-
公开(公告)号:US20240293463A1
公开(公告)日:2024-09-05
申请号:US18643312
申请日:2024-04-23
申请人: The Regents of the University of California , Seattle Children’s Hospital DBA Seattle Children’s Research Institute
发明人: Yvonne Y. Chen , Eugenia Zah , Michael C. Jensen
IPC分类号: A61K35/17 , A61K38/00 , A61K39/00 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/46 , C12N5/0783
CPC分类号: A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70596 , C07K16/2803 , C07K16/2887 , C07K16/46 , C12N5/0636 , A61K38/00 , A61K2039/505 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/40 , C12N2510/00
摘要: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
-
公开(公告)号:US11160833B2
公开(公告)日:2021-11-02
申请号:US17028701
申请日:2020-09-22
发明人: Yvonne Y. Chen , Eugenia Zah , Michael C. Jensen
IPC分类号: C07K16/00 , C12P21/08 , G01N33/53 , G01N33/567 , C12N5/00 , C12N5/16 , A61K35/17 , C07K16/46 , C12N5/0783 , C07K16/28 , C07K14/725 , C07K14/705 , C07K1/00 , A61K38/00 , A61K39/00
摘要: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
-
公开(公告)号:US11253546B2
公开(公告)日:2022-02-22
申请号:US15535972
申请日:2015-12-14
发明人: Yvonne Y. Chen , Eugenia Zah , Michael C. Jensen
IPC分类号: A61K39/395 , A61K39/40 , A61K35/17 , C07K16/46 , C12N5/0783 , C07K16/28 , C07K14/725 , C07K14/705 , C07K16/00 , A61K38/00 , A61K39/00
摘要: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
-
公开(公告)号:US20240261334A1
公开(公告)日:2024-08-08
申请号:US18623246
申请日:2024-04-01
申请人: The Regents of the University of California , Seattle Children's Hospital DBA Seattle Children's Research Institute
发明人: Yvonne Y. Chen , Eugenia Zah , Michael C. Jensen
IPC分类号: A61K35/17 , A61K38/00 , A61K39/00 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/46 , C12N5/0783
CPC分类号: A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70596 , C07K16/2803 , C07K16/2887 , C07K16/46 , C12N5/0636 , A61K38/00 , A61K2039/505 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/40 , C12N2510/00
摘要: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
-
公开(公告)号:US12053491B2
公开(公告)日:2024-08-06
申请号:US18238210
申请日:2023-08-25
发明人: Yvonne Y. Chen , Eugenia Zah , Michael C. Jensen
IPC分类号: A61K35/17 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/46 , C12N5/0783 , A61K38/00 , A61K39/00
CPC分类号: A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70596 , C07K16/2803 , C07K16/2887 , C07K16/46 , C12N5/0636 , A61K38/00 , A61K2039/505 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/40 , C12N2510/00
摘要: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
-
公开(公告)号:US11944648B2
公开(公告)日:2024-04-02
申请号:US18238210
申请日:2023-08-25
发明人: Yvonne Y. Chen , Eugenia Zah , Michael C. Jensen
IPC分类号: A61K35/17 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/46 , C12N5/0783 , A61K38/00 , A61K39/00
CPC分类号: A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70596 , C07K16/2803 , C07K16/2887 , C07K16/46 , C12N5/0636 , A61K38/00 , A61K2039/505 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/40 , C12N2510/00
摘要: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
-
公开(公告)号:US20240024359A1
公开(公告)日:2024-01-25
申请号:US18238210
申请日:2023-08-25
申请人: The Regents of the University of California , Seattle Children's Hospital DBA Seattle Children's Research Institute
发明人: Yvonne Y. Chen , Eugenia Zah , Michael C. Jensen
IPC分类号: A61K35/17 , C07K16/46 , C12N5/0783 , C07K16/28 , C07K14/725 , C07K14/705
CPC分类号: A61K35/17 , C07K16/46 , C12N5/0636 , C07K16/2803 , C07K16/2887 , C07K14/7051 , C07K14/70521 , C07K14/70596 , A61K38/00
摘要: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
-
-
-
-
-
-